NNVC - NanoViricides Inc Stock Price, Fair Value and News
1.13USD-0.01 (-0.88%)Market Closed
Market Summary
USD1.13-0.01
Market Closed-0.88%
NNVC Stock Price
View Fullscreen
NNVC RSI Chart
NNVC Valuation
NNVC Price/Sales (Trailing)
NNVC Profitability
NNVC Fundamentals
NNVC Earnings
Breaking Down NNVC Revenue
Last 7 days
-3.4%
Last 90 days
9.6%
Trailing 12 Months
-10.9%
How does NNVC drawdown profile look like?
NNVC Financial Health
NNVC Investor Care
Tracking the Latest Insider Buys and Sells of NanoViricides Inc
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
| Aug 08, 2022 | diwan anil | gifted | - | - | -94,471 | president |
Which funds bought or sold NNVC recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
| Apr 16, 2024 | Asset Dedication, LLC | unchanged | - | 1,000 | 2,000 | -% |
| Apr 12, 2024 | Game Plan Financial Advisors, LLC | sold off | -100 | -459 | - | -% |
| Apr 05, 2024 | NBC SECURITIES, INC. | unchanged | - | - | 3,000 | -% |
| Mar 11, 2024 | VANGUARD GROUP INC | unchanged | - | -146,693 | 467,584 | -% |
| Feb 26, 2024 | Virtu Financial LLC | new | - | 17,000 | 17,000 | -% |
| Feb 15, 2024 | Main Street Group, LTD | new | - | 204 | 204 | -% |
| Feb 14, 2024 | CITADEL ADVISORS LLC | new | - | 17,157 | 17,157 | -% |
| Feb 14, 2024 | Royal Bank of Canada | unchanged | - | -10,000 | 31,000 | -% |
| Feb 14, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | unchanged | - | -18,892 | 60,220 | -% |
Are Funds Buying or Selling NNVC?
Calls
Puts
Net Call Options
No. of Funds
Unveiling NanoViricides Inc's Major ShareHolders
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 16, 2021 | cvi investments, inc. | - | 0 | SC 13G/A | |
| Feb 12, 2021 | altium capital management lp | 0% | 0 | SC 13G/A | |
| Jan 26, 2021 | empery asset management, lp | 0.00% | 0 | SC 13G/A | |
| Jan 04, 2021 | sabby management, llc | 12.% | 0 | SC 13G/A | |
| Jul 20, 2020 | altium capital management lp | 7.2% | 750,000 | SC 13G | |
| May 29, 2020 | cvi investments, inc. | 5.1% | 466,667 | SC 13G | |
| Jan 27, 2020 | empery asset management, lp | 5.67% | 381,728 | SC 13G | |
| Jan 24, 2020 | sabby management, llc | 9.51% | 640,000 | SC 13G/A |
Recent SEC filings of NanoViricides Inc
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Apr 05, 2024 | 8-K | Current Report | |
| Apr 05, 2024 | 424B5 | Prospectus Filed | |
| Feb 16, 2024 | 8-K | Current Report | |
| Feb 14, 2024 | 10-Q | Quarterly Report | |
| Jan 19, 2024 | 8-K | Current Report |
Peers (Alternatives to NanoViricides Inc)
| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
MRNA | 41.6B | 6.8B | 2.33% | -21.90% | -8.82 | 6.07 | -64.45% | -156.37% |
HILS | 22.4B | 152.6K | -0.77% | 465779.94% | -2.4K | 146.8K | - | -9.98% |
ALNY | 18.1B | 1.8B | -0.30% | -28.67% | -41.14 | 9.91 | 76.23% | 61.08% |
BMRN | 17.2B | 2.4B | 8.14% | -4.26% | 102.64 | 7.11 | 15.42% | 18.43% |
INCY | 11.6B | 3.7B | -9.39% | -31.39% | 19.44 | 3.14 | 8.87% | 75.42% |
| MID-CAP | ||||||||
APLS | 5.9B | 396.6M | -12.04% | -45.12% | -11.11 | 14.81 | 425.83% | 18.94% |
BBIO | 4.5B | - | -13.93% | 67.39% | -6.85 | 60.35 | 54.84% | -34.79% |
AXSM | 3.5B | 270.6M | -9.40% | -0.33% | -14.47 | 12.79 | 440.80% | -27.84% |
ARWR | 2.9B | 240.7M | -12.61% | -20.79% | -9.93 | 12.18 | -1.03% | -92.09% |
ACAD | 2.8B | 726.4M | -6.74% | -16.88% | -45.01 | 3.8 | 40.45% | 71.62% |
| SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | -6.36% | -10.84% | 24.96 | 4.48 | 85.90% | -14.05% |
NVAX | 580.8M | 983.7M | -10.64% | -48.02% | -1.07 | 0.59 | -50.36% | 17.16% |
CRBP | 372.9M | 881.7K | 8.01% | 271.09% | -8.36 | 466.16 | -77.61% | -5.33% |
INO | 237.4M | 4.9M | -10.76% | 0.48% | -1.76 | 48.79 | -54.97% | 51.71% |
IBIO | 6.6M | 2.1M | 76.15% | 62.71% | -0.24 | 2.14 | -13.45% | 66.37% |
NanoViricides Inc News
Latest updates
NanoViricides Inc Earnings Report: Key Takeaways & Analysis
Balance Sheet
(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
| Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
| Assets | -13.1% | 13.00 | 15.00 | 17.00 | 19.00 | 20.00 | 22.00 | 23.00 | 25.00 | 27.00 | 29.00 | 30.00 | 33.00 | 28.00 | 32.00 | 24.00 | 17.00 | 12.00 | 12.00 | 13.00 | 15.00 | 15.00 |
| Current Assets | -25.6% | 5.00 | 7.00 | 8.00 | 10.00 | 12.00 | 13.00 | 14.00 | 16.00 | 18.00 | 20.00 | 21.00 | 23.00 | 18.00 | 22.00 | 14.00 | 6.00 | 1.00 | 1.00 | 3.00 | 5.00 | 4.00 |
| Cash Equivalents | -25.7% | 5.00 | 7.00 | 8.00 | 10.00 | 11.00 | 13.00 | 14.00 | 16.00 | 17.00 | 20.00 | 21.00 | 23.00 | 18.00 | 22.00 | 14.00 | 6.00 | 1.00 | 1.00 | 3.00 | 4.00 | 4.00 |
| Net PPE | -2.3% | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 11.00 |
| Liabilities | -61.2% | 1.00 | 2.00 | 2.00 | 2.00 | 1.00 | 1.00 | 0.00 | - | - | - | - | - | - | - | - | - | - | - | - | 3.00 | - |
| Current Liabilities | 0.3% | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 1.00 | 0.00 | 2.00 | 2.00 | 2.00 | 4.00 | 3.00 | 3.00 | 1.00 | 1.00 |
| Shareholder's Equity | -4.0% | 12.00 | 13.00 | 15.00 | 18.00 | 20.00 | 22.00 | 23.00 | 25.00 | 26.00 | 28.00 | 30.00 | 32.00 | 28.00 | 30.00 | 22.00 | 14.00 | 8.00 | 9.00 | 11.00 | 13.00 | 14.00 |
| Retained Earnings | -1.6% | -135 | -133 | -131 | -127 | -125 | -124 | -122 | -121 | -118 | -117 | -114 | -112 | -110 | -107 | -105 | -103 | -95.61 | -93.70 | -92.12 | -89.90 | -87.76 |
| Additional Paid-In Capital | 1.1% | 148 | 146 | 146 | 146 | 146 | 146 | 146 | 145 | 145 | 145 | 144 | 144 | 138 | 138 | 127 | 118 | 103 | 103 | 103 | 103 | 102 |
| Accumulated Depreciation | - | - | - | - | - | - | 6.00 | 6.00 | 6.00 | 6.00 | 5.00 | 5.00 | 5.00 | - | 5.00 | 5.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| Shares Outstanding | 0.3% | 12.00 | 12.00 | 12.00 | 12.00 | 12.00 | 12.00 | 12.00 | 12.00 | 12.00 | 12.00 | 12.00 | 11.00 | 11.00 | - | - | - | - | - | - | - | - |
| Float | - | - | - | - | - | 12.00 | - | - | - | 41.00 | - | - | - | 30.00 | - | - | - | - | - | - | - | 10.00 |
Cashflow (Last 12 Months)
(In Thousands)
| Cashflow (Quarterly) | (In Thousands) | |||||||||||||||||||||
| Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
| Cashflow From Operations | -41.7% | -1,700 | -1,200 | -1,500 | -1,766 | -1,400 | -1,032 | -1,397 | -1,655 | -2,114 | -724 | -2,227 | -1,434 | -2,315 | -2,235 | -1,708 | -2,396 | -1,126 | -1,434 | -1,671 | -2,010 | -2,158 |
| Share Based Compensation | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cashflow From Investing | - | - | - | - | - | - | - | -170 | - | - | - | - | -110 | - | - | - | - | - | - | - | - | - |
| Cashflow From Financing | - | - | - | - | - | -23.84 | -70.95 | -32.71 | -69.29 | -61.37 | -71.34 | -70.50 | 6,052 | -1,074 | 10,354 | 9,316 | 7,795 | 959 | -242 | - | 2,350 | - |
NNVC Income Statement
2023-12-31Condensed Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | |
| OPERATING EXPENSES | ||||
| Research and development | $ 1,573,879 | $ 1,170,710 | $ 3,040,544 | $ 2,283,369 |
| General and administrative | 610,877 | 663,284 | 1,175,803 | 1,172,985 |
| Total operating expenses | 2,184,756 | 1,833,994 | 4,216,347 | 3,456,354 |
| LOSS FROM OPERATIONS | (2,184,756) | (1,833,994) | (4,216,347) | (3,456,354) |
| OTHER INCOME (EXPENSE) | ||||
| Interest income | 83,134 | 88,954 | 182,472 | 141,516 |
| Interest expense | (13,315) | (94) | (49,808) | (938) |
| Other income (expense), net | 69,819 | 88,860 | 132,664 | 140,578 |
| NET LOSS | $ (2,114,937) | $ (1,745,134) | $ (4,083,683) | $ (3,315,776) |
| Net loss/Weighted average common shares | ||||
| Net loss per common share- basic | $ (0.18) | $ (0.15) | $ (0.35) | $ (0.29) |
| Net loss per common share- diluted | $ (0.18) | $ (0.15) | $ (0.35) | $ (0.29) |
| Weighted average common shares outstanding - basic | 11,745,906 | 11,610,303 | 11,732,349 | 11,601,335 |
| Weighted average common shares outstanding - diluted | 11,745,906 | 11,610,303 | 11,732,349 | 11,601,335 |
NNVC Balance Sheet
2023-12-31Condensed Balance Sheets - USD ($) | Dec. 31, 2023 | Jun. 30, 2023 |
|---|---|---|
| CURRENT ASSETS: | ||
| Cash and cash equivalents | $ 5,245,374 | $ 8,149,808 |
| Prepaid expenses | 72,442 | 295,486 |
| Total current assets | 5,317,816 | 8,445,294 |
| Property and equipment, net | 7,746,092 | 8,106,647 |
| Intangible assets, net | 329,443 | 333,578 |
| OTHER ASSETS | ||
| Service agreements | 8,859 | 14,361 |
| Total assets | 13,402,210 | 16,899,880 |
| CURRENT LIABILITIES: | ||
| Accrued expenses | 180,372 | 143,760 |
| Total current liabilities | 951,074 | 534,250 |
| Other non-current liability- related party | 1,500,000 | |
| Total liabilities | 951,074 | 2,034,250 |
| COMMITMENTS AND CONTINGENCIES | ||
| STOCKHOLDERS' EQUITY: | ||
| Common stock, $0.00001 par value; 150,000,000 shares authorized, 11,778,643 and 11,698,497 shares issued and outstanding, at December 31, 2023 and June 30, 2023, respectively | 117 | 116 |
| Additional paid-in capital | 147,615,441 | 145,946,258 |
| Accumulated deficit | (135,164,431) | (131,080,749) |
| Total stockholders' equity | 12,451,136 | 14,865,630 |
| Total liabilities and stockholders' equity | 13,402,210 | 16,899,880 |
| Nonrelated party | ||
| CURRENT LIABILITIES: | ||
| Accounts payable | 266,663 | 157,056 |
| Related party | ||
| CURRENT LIABILITIES: | ||
| Accounts payable | 504,039 | 233,434 |
| Series A convertible preferred stock | ||
| STOCKHOLDERS' EQUITY: | ||
| Series A convertible preferred stock, $0.00001 par value, 10,000,000 shares designated, 890,511 and 547,674 shares issued and outstanding, at December 31, 2023 and June 30, 2023, respectively | $ 9 | $ 5 |
| CEO | Dr. Anil R. Diwan Ph.D. |
|---|---|
| WEBSITE | nanoviricides.com |
| INDUSTRY | Biotechnology |
| EMPLOYEES | 17 |